Latest Insider Transactions at Biolife Solutions Inc (BLFS)
This section provides a real-time view of insider transactions for Biolife Solutions Inc (BLFS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOLIFE SOLUTIONS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOLIFE SOLUTIONS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 17
2021
|
Roderick De Greef President and CEO |
SELL
Open market or private sale
|
Direct |
4,424
-2.3%
|
$181,384
$41.55 P/Share
|
|
Feb 17
2021
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
1,842
-2.29%
|
$75,522
$41.55 P/Share
|
|
Feb 17
2021
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
9,917
-3.52%
|
$406,597
$41.55 P/Share
|
|
Feb 17
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,640
-2.12%
|
$190,240
$41.55 P/Share
|
|
Feb 17
2021
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
3,281
-4.19%
|
$134,521
$41.55 P/Share
|
|
Feb 16
2021
|
Todd Berard Chief Marketing Officer |
SELL
Open market or private sale
|
Direct |
12,324
-8.8%
|
$542,256
$44.48 P/Share
|
|
Feb 16
2021
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,324
+8.09%
|
$12,324
$1.64 P/Share
|
|
Feb 16
2021
|
Andrew G Hinson Director |
SELL
Open market or private sale
|
Direct |
2,500
-12.85%
|
$112,500
$45.67 P/Share
|
|
Feb 08
2021
|
Roderick De Greef President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,552
+14.08%
|
-
|
|
Feb 08
2021
|
Roderick De Greef President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
4,740
+2.86%
|
-
|
|
Feb 08
2021
|
Todd Berard Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,982
+13.89%
|
-
|
|
Feb 08
2021
|
Todd Berard Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,610
+5.08%
|
-
|
|
Feb 08
2021
|
Michael Rice |
BUY
Exercise of conversion of derivative security
|
Direct |
70,994
+20.15%
|
-
|
|
Feb 08
2021
|
Michael Rice |
BUY
Grant, award, or other acquisition
|
Direct |
7,511
+3.45%
|
-
|
|
Feb 08
2021
|
Marcus Schulz Chief Revenue Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,912
+6.78%
|
-
|
|
Feb 08
2021
|
Sarah Aebersold Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,795
+11.8%
|
-
|
|
Feb 08
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,196
+13.19%
|
-
|
|
Feb 08
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,891
+2.57%
|
-
|
|
Feb 08
2021
|
Karen A. Foster Chief Quality and Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
23,336
+22.98%
|
-
|
|
Feb 08
2021
|
Karen A. Foster Chief Quality and Operations |
BUY
Grant, award, or other acquisition
|
Direct |
4,157
+7.04%
|
-
|
|
Feb 05
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
40,000
-1.2%
|
$1,600,000
$40.9 P/Share
|
|
Feb 04
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,483
-9.29%
|
$739,320
$40.02 P/Share
|
|
Feb 04
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,483
+8.5%
|
$18,483
$1.12 P/Share
|
|
Feb 04
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,538
-0.26%
|
$341,520
$40.65 P/Share
|
|
Feb 02
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,484
-9.29%
|
$739,360
$40.23 P/Share
|
|
Feb 02
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,484
+8.5%
|
$18,484
$1.12 P/Share
|
|
Feb 01
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
18,484
-9.29%
|
$702,392
$38.71 P/Share
|
|
Feb 01
2021
|
Aby J. Mathew EVP & Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,484
+8.5%
|
$18,484
$1.12 P/Share
|
|
Jan 25
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
50,000
-1.48%
|
$2,050,000
$41.58 P/Share
|
|
Jan 22
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,811
-0.87%
|
$1,252,062
$42.48 P/Share
|
|
Jan 20
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,182
-0.85%
|
$1,196,462
$41.03 P/Share
|
|
Jan 19
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
40,000
-1.15%
|
$1,600,000
$40.3 P/Share
|
|
Jan 15
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
29,338
-0.84%
|
$1,173,520
$40.62 P/Share
|
|
Jan 14
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,152
-0.63%
|
$952,536
$43.08 P/Share
|
|
Jan 12
2021
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
2,000
-5.11%
|
$82,000
$41.01 P/Share
|
|
Jan 12
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,435
-0.24%
|
$337,400
$40.4 P/Share
|
|
Jan 11
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
80,000
-0.74%
|
$3,200,000
$40.23 P/Share
|
|
Jan 08
2021
|
Marcus Schulz Chief Revenue Officer |
SELL
Open market or private sale
|
Direct |
293
-0.74%
|
$11,427
$39.01 P/Share
|
|
Jan 07
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,000
-0.82%
|
$1,170,000
$39.55 P/Share
|
|
Jan 06
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,075
-0.41%
|
$618,075
$41.53 P/Share
|
|
Jan 05
2021
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
18,948
-0.51%
|
$795,816
$42.54 P/Share
|
|
Dec 01
2020
|
Michael Rice |
SELL
Open market or private sale
|
Direct |
813
-0.4%
|
$28,455
$35.49 P/Share
|
|
Dec 01
2020
|
Karen A. Foster Chief Quality and Operations |
SELL
Open market or private sale
|
Direct |
166
-0.33%
|
$5,810
$35.49 P/Share
|
|
Dec 01
2020
|
Aby J. Mathew EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
380
-0.21%
|
$13,300
$35.49 P/Share
|
|
Nov 24
2020
|
Thomas Girschweiler Director |
SELL
Open market or private sale
|
Indirect |
1,600,000
-97.1%
|
$35,200,000
$22.5 P/Share
|
|
Nov 24
2020
|
Casdin Partners Master Fund, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,600,000
+17.7%
|
$35,200,000
$22.5 P/Share
|
|
Nov 19
2020
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
36,848
-0.99%
|
$1,215,984
$33.35 P/Share
|
|
Nov 18
2020
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
40,000
-1.06%
|
$1,280,000
$32.33 P/Share
|
|
Nov 17
2020
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
40,000
-1.05%
|
$1,240,000
$31.31 P/Share
|
|
Nov 16
2020
|
Walter Villiger > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
36,957
-0.96%
|
$1,145,667
$31.68 P/Share
|